Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00170768|
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : January 23, 2008
|Condition or disease||Intervention/treatment||Phase|
|Healthy Volunteers||Drug: Darifenacin Drug: Oxybutynin Drug: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||150 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over|
|Study Start Date :||February 2005|
|Study Completion Date :||May 2005|
Darifenacin modified release 7,5 mg tablets once daily titrated to 15 mg once daily
Other Name: Enablex
Active Comparator: 2
Oxybutynin extended release 10 mg tablet once daily titrated to 15 mg, then to 20 mg once daily
Placebo Comparator: 3
Placebo once daily tablet (sham titration)
- Cognitive effect: measure of accuracy of delayed recall name-phase association test at week 3.
- Cognitive effect: measure of accuracy of delayed recall name-phase association test at week 1 & 2.
- Effects on other cognitive domains measured by various tests at week 1,2 and 3.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00170768
|United States, District of Columbia|
|Washington Neuropsychological Institute LLC Georgetown|
|Washington, District of Columbia, United States, 20016|
|Study Chair:||Novartis||East Hanover NJ|